Delivery Order SPE2DB22D2009-SPE2DB25FM0TC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,440.70 for XOLAIR 150 mg/mL syringes, with an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $10,805.10 to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $20.79K delivery order on August 6, 2025, for Xolair 300 mg/2 mL syringes, with completion expected by August 27, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania headquarters. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99M prime...
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order for XOLAIR 150 mg/ml syringes valued at $108,051.00 under a firm fixed-price contract. This non-set-aside award was issued on July 31, 2025, with an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. XOLAIR is a biologic medication used to treat moderate-to-severe allergic asthma and other...
- The Defense Logistics Agency awarded a $3,376.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on May 2, 2025, with completion scheduled for May 23, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,601.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for Xolair 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. The contract, issued on June 24, 2025, with an ultimate completion date of July 16, 2025, was awarded on a non-competitive, firm fixed-price basis. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM0TCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,184.74 to AmerisourceBergen Drug Corp for Xolair 300 mg/2 mL syringes on August 6, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical supply will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xolair is a biologic immunosuppressant medication used in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medical products to federal healthcare systems, including the Defense Health Agency, U.S. Coast Guard, and military medical facilities worldwide. This delivery order exemplifies the company's role as a critical vendor within the federal medical supply chain, fulfilling specialized pharmaceutical requirements to support military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/6/25 |